Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will participate in five upcoming investor conferences during February and March 2025. The company will be featured at:

• B. Riley Securities Precision Oncology & Radiopharma Conference (Feb 28) - participating in a panel on Nectin-4 Targeting Therapies
• TD Cowen 45th Annual Health Care Conference (Mar 4) - delivering a presentation with webcast availability
• Wedbush Securities Cardiometabolic Conference (Mar 10) - joining a panel on alternative obesity targets beyond GLP1s
• Leerink Partners Global Healthcare Conference (Mar 12) - presenting with webcast access
• BMO 2025 Obesity Summit (Mar 25) - participating in an Emerging Technologies panel

These appearances highlight Corbus' strategic focus on both oncology and obesity/cardiometabolic therapeutic areas, providing investors multiple opportunities to engage with company leadership.

Positive

• Corbus Pharmaceuticals is actively engaging with investors through multiple high-profile conferences
• The company is pursuing research in two promising therapeutic areas: oncology and obesity/metabolic disorders
• Webcasts for two major presentations provide broader investor accessibility
• CEO Yuval Cohen's direct involvement suggests strong leadership presence in investor relations

Negative

• The press release doesn't mention specific drug candidates or development progress
• No financial updates or business developments were included
• The company is participating in panels rather than headlining some events, suggesting possibly earlier-stage programs

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences.

B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Format: Panel and one-on-one investor meetings
Panel Title: Unlocking the Full Potential of Nectin-4 Targeting Therapies
Date: February 28, 2025
Time: 8:00 a.m. ET

TD Cowen 45^th Annual Health Care Conference
Format: Presentation and one-on-one investor meetings
Date: March 4, 2025
Time: 1:50 p.m. ET
Webcast: Click here

Wedbush Securities Cardiometabolic Conference
Format: Panel
Panel Title: The Future of Fat: Exploring Alternative Targets in Obesity Beyond GLP1s
Date: March 10, 2025
Time: 10:05 a.m. ET

Leerink Partners Global Healthcare Conference 2025
Format: Presentation and one-on-one investor meetings
Date: March 12, 2025
Time: 1:40 p.m. ET
Webcast: Click here

BMO 2025 Obesity Summit
Format: Panel and one-on-one investor meetings
Panel Title: Emerging Technologies
Date: March 25, 2025
Time: 1:15 p.m. ET

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

What investor conferences will Corbus Pharmaceuticals (CRBP) attend in February-March 2025?

Corbus Pharmaceuticals will participate in five investor conferences: B. Riley Securities Precision Oncology Conference (Feb 28), TD Cowen Health Care Conference (Mar 4), Wedbush Cardiometabolic Conference (Mar 10), Leerink Partners Global Healthcare Conference (Mar 12), and BMO Obesity Summit (Mar 25).

Which therapeutic areas is Corbus Pharmaceuticals (CRBP) focusing on based on their conference participation?

Based on their conference participation, Corbus Pharmaceuticals is focusing on oncology (specifically Nectin-4 targeting therapies) and metabolic diseases (particularly obesity treatments beyond GLP1s), as evidenced by their panels at specialized conferences in these therapeutic areas.

Will Corbus Pharmaceuticals (CRBP) provide webcasts of their investor conference presentations?

Yes, Corbus Pharmaceuticals will provide webcasts for two of their five upcoming presentations - the TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 12, 2025.

What panel discussions will Corbus Pharmaceuticals (CRBP) participate in during February-March 2025?

Corbus will participate in three panel discussions: "Unlocking the Full Potential of Nectin-4 Targeting Therapies" at B. Riley Securities (Feb 28), "The Future of Fat: Exploring Alternative Targets in Obesity Beyond GLP1s" at Wedbush (Mar 10), and "Emerging Technologies" at BMO Obesity Summit (Mar 25).

When will Corbus Pharmaceuticals (CRBP) present at the TD Cowen Annual Health Care Conference?

Corbus Pharmaceuticals will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:50 p.m. ET, with a webcast available for investors who cannot attend in person.

What is Corbus Pharmaceuticals' (CRBP) involvement in obesity treatment research?

Corbus Pharmaceuticals is involved in obesity treatment research, specifically exploring alternative targets beyond GLP1s, as indicated by their participation in the Wedbush Cardiometabolic Conference panel "The Future of Fat" and the BMO 2025 Obesity Summit's "Emerging Technologies" panel.